Research on biomarkers for diagnosing and assessing bradykinin angioedema
Research of Biomarkers Associated With the Diagnosis and Severity of Bradykinin Angioedema
University Hospital, Lille · NCT04963634
This study is trying to find specific markers in the blood that can help doctors better diagnose and understand the severity of bradykinin angioedema in patients who experience swelling episodes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT04963634 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers that can aid in the diagnosis and severity assessment of bradykinin angioedema, a condition characterized by unpredictable swelling episodes. The research focuses on patients with various forms of bradykinin angioedema, including hereditary and acquired types, as well as those related to certain medications. By biobanking samples from these patients, the study seeks to improve diagnostic accuracy and predict the severity of attacks, which is currently a challenge for healthcare providers.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with diagnosed bradykinin angioedema or histamine-mediated angioedema who are scheduled for routine blood collection.
Not a fit: Patients under 18 years old or those without a confirmed diagnosis of angioedema may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools and treatment strategies for patients suffering from bradykinin angioedema.
How similar studies have performed: While there is ongoing research in the field, the specific approach of identifying biomarkers for bradykinin angioedema is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group 1 : Patients with bradykinin angioedema * Patient with biologically proven hereditary angioedema with C1 inhibitor deficiency, * Or a patient with bradykinin angioedema related to a plasminogen or factor XII mutation, * Or patients with bradykinin angioedema related to ACE inhibitors or ARB2, * Or patient with acquired bradykinin angioedema due to C1 inhibitor deficiency, * Age \> or = 18 years with the capacity to understand the requirements of the study and to give a non-opposition * Having a blood collection scheduled as part of routine care * Being insured by social security Group 2 : Patients with histamine-mediated angioedema * Patient with idiopathic histamine angioedema as determined by the referring physician * Age \> or = 18 years with the capacity to understand the requirements of the study and to give a non-opposition * Having a blood collection scheduled as part of routine care * Being insured by social security Exclusion Criteria: * Minors or protected adults, * Pregnant or breastfeeding woman, * Person deprived of liberty, * Person in an emergency situation, * Person having refused or unable to give their non-opposition
Where this trial is running
Lille
- Hop Claude Huriez Chu Lille — Lille, France (RECRUITING)
Study contacts
- Principal investigator: David Launay, MD,PhD — University Hospital, Lille
- Study coordinator: David Launay, MD,PhD
- Email: david.launay@chru-lille.fr
- Phone: 0320445962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Angio Edema, Angioedema, Bradykinin, Biomarker, Biobanking